시장보고서

상품코드

1762315

세계의 GLP-1 시장, 규모, 점유율, 산업 분석 보고서 : 투여 경로별, 분자 유형별, 사용 활성 화합물별, GLP-1 작용제 유형별, 타겟 적응증별, 지역별, 예측(2025-2034년)

GLP-1 Market Size, Share, & Industry Analysis Report: By Route of Administration (Oral and Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, and By Region - Market Forecast, 2025-2034

발행일: 2025년 05월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 129 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 GLP-1 시장 규모는 2034년까지 1,339억 2,000만 달러에 달할 것으로 예측됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.

GLP-1(글루카곤 유사 펩타이드-1)은 인크레틴 호르몬의 일종으로 인슐린 분비를 촉진하고 글루카곤의 분비를 유도하여 당 대사에 중요한 역할을 합니다. 치료적으로 GLP-1 수용체 작용제는 2형 당뇨병 치료 및 체중 조절을 위해 사용되고 있으며, GLP-1 수용체 작용제는 2형 당뇨병 치료 및 체중 조절뿐만 아니라 비만 및 심혈관계 위험과 같은 보다 광범위한 만성 질환 관리의 틀에 통합되고 있습니다. GLP-1 수용체 작용제는 그 임상적 유용성이 널리 인식됨에 따라 진화하는 치료 가이드라인에 부합하는 다중 표적 약물로 채택되고 있으며, GLP-1 수용체 작용제는 그 임상적 유용성이 널리 인식됨에 따라 치료 가이드라인에 부합하는 다중 표적 약물로 채택되고 있습니다. 이러한 유용성 확대로 인해 전반적인 결과 중심의 치료 솔루션을 원하는 의료진과 환자들의 관심이 높아지고 있습니다.

제약사들이 주도하는 지속적인 기술 혁신은 약물 전달, 편의성, 환자 순응도를 향상시키는 것을 목표로 하고 있습니다. 제약사들은 부작용이 적고 투여 횟수가 적으며 대사 결과를 개선하는 차세대 제제 및 병용요법에 대한 투자를 늘리고 있습니다. 이와 함께 개인화된 치료 프로토콜에 대한 관심이 높아지면서 환자 프로파일에 맞춘 정밀 기반 GLP-1 치료제의 개발이 가속화되고 있습니다. 이러한 발전은 전반적으로 보다 개인화된 장기적인 질병 관리 전략으로 시장이 이동하고 있음을 시사하고 있습니다.

GLP-1 시장 보고서 하이라이트

GLP-1 작용제 유형별로는 장시간 작용형 GLP-1 작용제가 투여 간격 연장, 환자 순응도 향상, 일관된 임상 결과 등을 이유로 2024년 시장을 주도했습니다.

투여 경로별로는 경구용 GLP-1 제제가 예측 기간 동안 가장 빠르게 성장할 것으로 예측됩니다.

2024년에는 북미가 가장 큰 매출 점유율을 차지했고, 이는 높은 당뇨병/비만율, 최첨단 의료 시스템, 혁신적인 치료법의 급속한 보급에 힘입은 것으로 분석됩니다.

아시아태평양은 생활습관 관련 대사성 질환의 급증과 의료 서비스 접근성 확대로 인해 가장 높은 성장이 예상됩니다.

세계 주요 시장 기업으로는 AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, Tonghua Dongbao Pharmaceutical. 등이 있습니다.

주요 조사 결과
서론
- GLP-1 시장 평가 : 지역, 2020-2034년
북미
- 분자 유형별, 2020-2034년
- 사용 활성 화합물별, 2020-2034년
- GLP-1 작용제 유형별, 2020년-2034년
- 투여 경로별, 2020-2034년
- 타겟 적응증별, 2020-2034년
- 미국
- 캐나다
유럽
- 분자 유형별, 2020-2034년
- 사용 활성 화합물별, 2020-2034년
- GLP-1 작용제 유형별, 2020년-2034년
- 투여 경로별, 2020-2034년
- 타겟 적응증별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
아시아태평양
- 분자 유형별, 2020-2034년
- 사용 활성 화합물별, 2020-2034년
- GLP-1 작용제 유형별, 2020년-2034년
- 투여 경로별, 2020-2034년
- 타겟 적응증별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 분자 유형별, 2020-2034년
- 사용 활성 화합물별, 2020-2034년
- GLP-1 작용제 유형별, 2020년-2034년
- 투여 경로별, 2020-2034년
- 타겟 적응증별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
라틴아메리카
- 분자 유형별, 2020-2034년
- 사용 활성 화합물별, 2020-2034년
- GLP-1 작용제 유형별, 2020년-2034년
- 투여 경로별, 2020-2034년
- 타겟 적응증별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카

제11장 경쟁 구도

확대와 인수 분석
- 확대
- 인수
제휴/협업/합의/공개

제12장 기업 개요

AstraZeneca
Boehringer Ingelheim
D&D Pharmatech
Eli Lilly
Hanmi Pharmaceutical
Novo Nordisk
Pfizer
Roche
Sanofi
Tonghua Dongbao Pharmaceutical

LSH 25.07.10

The GLP-1 Market market size is expected to reach USD 133.92 billion by 2034, according to a new study by Polaris Market Research. The report "GLP-1 Market Share, Size, Trends, Industry Analysis Report: By Route of Administration (Oral and Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

GLP-1 (glucagon-like peptide-1) is an incretin hormone that plays a major role in glucose metabolism by allowing insulin release and incorporating glucagon secretion. Therapeutically, GLP-1 receptor agonists are used to treat type 2 diabetes and support weight management. The growing integration of these therapies into broader chronic disease management frameworks extends their relevance beyond type 2 diabetes to conditions such as obesity and cardiovascular risk. GLP-1 receptor agonists are being adopted as multi-targeted agents that align with evolving treatment guidelines as their clinical benefits become more widely recognized. This expanded utility is promoting greater interest among healthcare providers and patients seeking holistic, outcome-driven care solutions.

The continuous innovation led by pharmaceutical companies aims to improve drug delivery, convenience, and patient compliance. Companies are increasingly investing in next-generation formulations and combination therapies that improve metabolic outcomes with fewer side effects and lower dosing frequency. Alongside this, a growing focus on individualized treatment protocols is encouraging the development of precision-based GLP-1 therapies tailored to patient profiles. These advancements collectively point to a shift in the market toward more personalized and long-term disease control strategies.

GLP-1 Market Report Highlights

In terms of type of GLP-1 agonist drugs, long-acting GLP-1 agonists led the market in 2024, for their extended dosing intervals, better patient compliance, and consistent clinical outcomes.

Based on route of administration, the oral GLP-1 segment is anticipated to grow fastest during the forecast period, driven by increasing preference for needle-free, convenient treatment alternatives.

In 2024, North America accounted for the largest revenue share, supported by high diabetes/obesity rates, cutting-edge healthcare systems, and rapid uptake of innovative therapies.

Asia Pacific is poised for the highest growth, fueled by surging lifestyle-related metabolic disorders and expanding healthcare accessibility.

A few global key market players include AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical.

Polaris Market Research has segmented the market report on the basis of route of administration, type of molecule, active compound used, type of GLP-1 agonist drug, target indication, and region:

By Type of Molecule Outlook (Revenue, USD Billion, 2020-2034)

Biologics

Small Molecules

By Active Compound Used Outlook (Revenue, USD Billion, 2020-2034)

Dulaglutide

Liraglutide

Orforglipron

Retatrutide

Semaglutide

Survodutide

Tirzepatide

Other Active Compounds

By Type of GLP-1 Agonist Drugs Outlook (Revenue, USD Billion, 2020-2034)

Long-acting GLP-1 Agonist

Short-acting GLP-1 Agonist

By Route of Administration Outlook (Revenue, USD Billion, 2020-2034)

Oral

Parenteral

By Target Indication Outlook (Revenue, USD Billion, 2020-2034)

Alzheimer's Disease

Non-Alcoholic Steatohepatitis

Obesity

Sleep Apnea

Type 2 Diabetes

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

Canada

Europe

Germany

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global GLP-1 Market Insights

4.1. GLP-1 Market - Material Snapshot
4.2. GLP-1 Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising prevalence of type 2 diabetes globally
  - 4.2.1.2. Increasing rates of obesity and related metabolic disorders
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High cost of GLP-1 drugs and affordability challenges
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. GLP-1 Market Material Trends
4.6. Value Chain Analysis

5. Global GLP-1 Market, by Type of Molecule

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global GLP-1 Market, by Type of Molecule, 2020-2034 (USD Billion)
5.3. Biologics
- 5.3.1. Global GLP-1 Market, by Biologics, by Region, 2020-2034 (USD Billion)
5.4. Small Molecules
- 5.4.1. Global GLP-1 Market, by Small Molecules, by Region, 2020-2034 (USD Billion)

6. Global GLP-1 Market, by Active Compound Used

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global GLP-1 Market, by Active Compound Used, 2020-2034 (USD Billion)
6.3. Dulaglutide
- 6.3.1. Global GLP-1 Market, by Dulaglutide, by Region, 2020-2034 (USD Billion)
6.4. Liraglutide
- 6.4.1. Global GLP-1 Market, by Liraglutide, by Region, 2020-2034 (USD Billion)
6.5. Orforglipron
- 6.5.1. Global GLP-1 Market, by Orforglipron, by Region, 2020-2034 (USD Billion)
6.6. Retatrutide
- 6.6.1. Global GLP-1 Market, by Retatrutide, by Region, 2020-2034 (USD Billion)
6.7. Semaglutide
- 6.7.1. Global GLP-1 Market, by Semaglutide, by Region, 2020-2034 (USD Billion)
6.8. Survodutide
- 6.8.1. Global GLP-1 Market, by Survodutide, by Region, 2020-2034 (USD Billion)
6.9. Tirzepatide
- 6.9.1. Global GLP-1 Market, by Tirzepatide, by Region, 2020-2034 (USD Billion)
6.10. Other Active Compounds
- 6.10.1. Global GLP-1 Market, by Other Active Compounds, by Region, 2020-2034 (USD Billion)

7. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
7.3. Long-acting GLP-1 Agonist
- 7.3.1. Global GLP-1 Market, by Long-acting GLP-1 Agonist, by Region, 2020-2034 (USD Billion)
7.4. Short-acting GLP-1 Agonist
- 7.4.1. Global GLP-1 Market, by Short-acting GLP-1 Agonist, by Region, 2020-2034 (USD Billion)

8. Global GLP-1 Market, by Route of Administration

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
8.3. Oral
- 8.3.1. Global GLP-1 Market, by Oral, by Region, 2020-2034 (USD Billion)
8.4. Parenteral
- 8.4.1. Global GLP-1 Market, by Parenteral, by Region, 2020-2034 (USD Billion)

9. Global GLP-1 Market, by Target Indication

9.1. Key Findings
9.2. Introduction
- 9.2.1. Global GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
9.3. ALZHEIMER'S DISEASE
- 9.3.1. Global GLP-1 Market, by ALZHEIMER'S DISEASE, 2020-2034 (USD Billion)
9.4. Non-Alcoholic Steatohepatitis
- 9.4.1. Global GLP-1 Market, by Non-Alcoholic Steatohepatitis, 2020-2034 (USD Billion)
9.5. Obesity
- 9.5.1. Global GLP-1 Market, by Obesity, 2020-2034 (USD Billion)
9.6. Sleep Apnea
- 9.6.1. Global GLP-1 Market, by Sleep Apnea, 2020-2034 (USD Billion)
9.7. Type 2 Diabetes
- 9.7.1. Global GLP-1 Market, by Type 2 Diabetes, 2020-2034 (USD Billion)

10. Global GLP-1 Market, by Geography

10.1. Key Findings
10.2. Introduction
- 10.2.1. GLP-1 Market Assessment, By Geography, 2020-2034 (USD Billion)
10.3. GLP-1 Market - North America
- 10.3.1. North America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.3.2. North America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.3.3. North America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.3.4. North America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.3.5. North America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.3.6. GLP-1 Market - US
  - 10.3.6.1. US: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.3.6.2. US: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.3.6.3. US: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.3.6.4. US: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.3.6.5. US: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.3.7. GLP-1 Market - Canada
  - 10.3.7.1. Canada: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.3.7.2. Canada: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.3.7.3. Canada: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.3.7.4. Canada: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.3.7.5. Canada: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
10.4. GLP-1 Market - Europe
- 10.4.1. Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.4.2. Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.4.3. Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.4.4. Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.4.5. Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.6. GLP-1 Market - UK
  - 10.4.6.1. UK: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.4.6.2. UK: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.4.6.3. UK: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.4.6.4. UK: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.4.6.5. UK: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.7. GLP-1 Market - France
  - 10.4.7.1. France: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.4.7.2. France: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.4.7.3. France: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.4.7.4. France: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.4.7.5. France: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.8. GLP-1 Market - Germany
  - 10.4.8.1. Germany: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.4.8.2. Germany: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.4.8.3. Germany: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.4.8.4. Germany: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.4.8.5. Germany: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.9. GLP-1 Market - Italy
  - 10.4.9.1. Italy: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.4.9.2. Italy: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.4.9.3. Italy: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.4.9.4. Italy: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.4.9.5. Italy: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.10. GLP-1 Market - Spain
  - 10.4.10.1. Spain: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.4.10.2. Spain: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.4.10.3. Spain: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.4.10.4. Spain: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.4.10.5. Spain: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.11. GLP-1 Market - Netherlands
  - 10.4.11.1. Netherlands: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.4.11.2. Netherlands: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.4.11.3. Netherlands: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.4.11.4. Netherlands: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.4.11.5. Netherlands: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.12. GLP-1 Market - Russia
  - 10.4.12.1. Russia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.4.12.2. Russia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.4.12.3. Russia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.4.12.4. Russia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.4.12.5. Russia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.13. GLP-1 Market - Rest of Europe
  - 10.4.13.1. Rest of Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.4.13.2. Rest of Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.4.13.3. Rest of Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.4.13.4. Rest of Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.4.13.5. Rest of Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
10.5. GLP-1 Market - Asia Pacific
- 10.5.1. Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.5.2. Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.5.3. Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.5.4. Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.5.5. Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.6. GLP-1 Market - China
  - 10.5.6.1. China: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.5.6.2. China: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.5.6.3. China: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.5.6.4. China: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.5.6.5. China: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.7. GLP-1 Market - India
  - 10.5.7.1. India: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.5.7.2. India: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.5.7.3. India: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.5.7.4. India: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.5.7.5. India: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.8. GLP-1 Market - Malaysia
  - 10.5.8.1. Malaysia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.5.8.2. Malaysia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.5.8.3. Malaysia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.5.8.4. Malaysia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.5.8.5. Malaysia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.9. GLP-1 Market - Japan
  - 10.5.9.1. Japan: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.5.9.2. Japan: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.5.9.3. Japan: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.5.9.4. Japan: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.5.9.5. Japan: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.10. GLP-1 Market - Indonesia
  - 10.5.10.1. Indonesia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.5.10.2. Indonesia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.5.10.3. Indonesia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.5.10.4. Indonesia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.5.10.5. Indonesia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.11. GLP-1 Market - South Korea
  - 10.5.11.1. South Korea: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.5.11.2. South Korea: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.5.11.3. South Korea: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.5.11.4. South Korea: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.5.11.5. South Korea: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.12. GLP-1 Market - Australia
  - 10.5.12.1. Australia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.5.12.2. Australia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.5.12.3. Australia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.5.12.4. Australia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.5.12.5. Australia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.13. GLP-1 Market - Rest of Asia Pacific
  - 10.5.13.1. Rest of Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.5.13.2. Rest of Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.5.13.3. Rest of Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.5.13.4. Rest of Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.5.13.5. Rest of Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
10.6. GLP-1 Market - Middle East & Africa
- 10.6.1. Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.6.2. Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.6.3. Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.6.4. Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.6.5. Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6.6. GLP-1 Market - Saudi Arabia
  - 10.6.6.1. Saudi Arabia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.6.6.2. Saudi Arabia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.6.6.3. Saudi Arabia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.6.6.4. Saudi Arabia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.6.6.5. Saudi Arabia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6.7. GLP-1 Market - UAE
  - 10.6.7.1. UAE: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.6.7.2. UAE: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.6.7.3. UAE: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.6.7.4. UAE: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.6.7.5. UAE: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6.8. GLP-1 Market - Israel
  - 10.6.8.1. Israel: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.6.8.2. Israel: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.6.8.3. Israel: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.6.8.4. Israel: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.6.8.5. Israel: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6.9. GLP-1 Market - South Africa
  - 10.6.9.1. South Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.6.9.2. South Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.6.9.3. South Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.6.9.4. South Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.6.9.5. South Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6.10. GLP-1 Market - Rest of Middle East & Africa
  - 10.6.10.1. Rest of Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.6.10.2. Rest of Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.6.10.3. Rest of Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.6.10.4. Rest of Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.6.10.5. Rest of Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
10.7. GLP-1 Market - Latin America
- 10.7.1. Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.7.2. Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.7.3. Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.7.4. Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.7.5. Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.7.6. GLP-1 Market - Mexico
  - 10.7.6.1. Mexico: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.7.6.2. Mexico: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.7.6.3. Mexico: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.7.6.4. Mexico: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.7.6.5. Mexico: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.7.7. GLP-1 Market - Brazil
  - 10.7.7.1. Brazil: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.7.7.2. Brazil: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.7.7.3. Brazil: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.7.7.4. Brazil: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.7.7.5. Brazil: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.7.8. GLP-1 Market - Argentina
  - 10.7.8.1. Argentina: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.7.8.2. Argentina: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.7.8.3. Argentina: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.7.8.4. Argentina: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.7.8.5. Argentina: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.7.9. GLP-1 Market - Rest of Latin America
  - 10.7.9.1. Rest of Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
  - 10.7.9.2. Rest of Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
  - 10.7.9.3. Rest of Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
  - 10.7.9.4. Rest of Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
  - 10.7.9.5. Rest of Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)

11. Competitive Landscape

11.1. Expansion and Acquisition Analysis
- 11.1.1. Expansion
- 11.1.2. Acquisitions
11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

12.1. AstraZeneca
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Benchmarking
- 12.1.4. Recent Development
12.2. Boehringer Ingelheim
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Benchmarking
- 12.2.4. Recent Development
12.3. D&D Pharmatech
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Benchmarking
- 12.3.4. Recent Development
12.4. Eli Lilly
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Benchmarking
- 12.4.4. Recent Development
12.5. Hanmi Pharmaceutical
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Benchmarking
- 12.5.4. Recent Development
12.6. Novo Nordisk
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Benchmarking
- 12.6.4. Recent Development
12.7. Pfizer
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Benchmarking
- 12.7.4. Recent Development
12.8. Roche
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Benchmarking
- 12.8.4. Recent Development
12.9. Sanofi
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Benchmarking
- 12.9.4. Recent Development
12.10. Tonghua Dongbao Pharmaceutical
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Benchmarking
- 12.10.4. Recent Development

세계의 GLP-1 시장, 규모, 점유율, 산업 분석 보고서 : 투여 경로별, 분자 유형별, 사용 활성 화합물별, GLP-1 작용제 유형별, 타겟 적응증별, 지역별, 예측(2025-2034년)

GLP-1 Market Size, Share, & Industry Analysis Report: By Route of Administration (Oral and Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, and By Region - Market Forecast, 2025-2034

GLP-1 시장 보고서 하이라이트

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 GLP-1 시장 인사이트

제5장 세계의 GLP-1 시장 : 분자 유형별

제6장 세계의 GLP-1 시장 : 사용 활성 화합물별

제7장 세계의 GLP-1 시장 : GLP-1 작용제 유형별

제8장 세계의 GLP-1 시장 : 투여 경로별

제9장 세계의 GLP-1 시장 : 타겟 적응증별

제10장 세계의 GLP-1 시장 : 지역